Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO- and PGE-2-dependent pathways

Human mesoangioblasts are currently in a phase I/II clinical trial for the treatment of patients with Duchenne muscular dystrophy. However, limitations associated with the finite life span of these cells combined with the significant numbers of mesoangioblasts required to treat all of the skeletal m...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ou, English, Karen, Tonlorenzi, Rossana, Cossu, Giulio, Saverio Tedesco, Francesco, Wood, Kathryn J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968899/
https://www.ncbi.nlm.nih.gov/pubmed/24715949
http://dx.doi.org/10.12688/f1000research.2-24.v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968899/
https://www.ncbi.nlm.nih.gov/pubmed/24715949
http://dx.doi.org/10.12688/f1000research.2-24.v1

Ejemplares similares